查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1922717

日本肺动脉高压治疗市场规模、份额、趋势及预测（按药物类别、给药途径、最终用户和地区划分，2026-2034年）

Japan Pulmonary Arterial Hypertension Drugs Market Size, Share, Trends and Forecast by Drug Class, Route of Administration, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 115 Pages | 商品交期: 5-7个工作天内

价格
简介目录

2025年，日本肺动脉高压治疗药物市场规模达4.97亿美元。 IMARC集团预测，到2034年，该市场规模将达到7.958亿美元，2026年至2034年的复合年增长率为5.37%。推动市场成长的关键因素包括：人们对该疾病的认识不断提高、诊断技术的进步、新治疗方法的推出、对个人化医疗的日益重视、研发方面的大量投资以及促进药物快速核准的监管支持。

日本肺动脉高压治疗市场趋势：

标靶治疗和个人化医疗的进展

推动日本肺动脉高压（PAH）治疗市场成长的关键趋势是日益重视标靶治疗和个人化医疗。这些先进治疗方法旨在透过特异性靶向参与疾病进展的分子路径（例如内皮素、一氧化氮和前列腺环素）来解决肺动脉高压的根本原因。生物标记识别和基因组检测技术的进步推动了个人化治疗的兴起，使得根据患者的基因谱进行更客製化的治疗成为可能，从而提高疗效并最大限度地减少副作用。这一上升趋势反映了PAH治疗的持续发展，其目标是透过精准医疗改善患者的治疗效果。

疾病意识提高和早期诊断取得进展

大众对肺动脉高压（PAH）的认知度不断提高，显着推动了日本PAH治疗市场的成长。 PAH曾因其症状特异性难以诊断，但如今患者和医疗服务提供者都已普遍认识到该疾病。主导的宣传活动，广泛普及了公众和医疗专业人员对早期诊断和适当介入重要性的认识。同时，心臟超音波图、右心导管检查和生物标记等诊断技术的进步，使得疾病的早期发现成为可能，从而推动了对PAH治疗需求的成长。此外，日本PAH确诊患者人数也逐渐增加，这印证了公众认知度提高和早期发现的正面影响。这种认知度的提升正在刺激治疗需求，并加速市场进一步扩张。

本报告解答的关键问题

  • 日本肺动脉高压治疗市场目前发展状况如何？未来几年又将如何发展？
  • 日本肺动脉高压治疗市场依药物类别是如何分類的？
  • 日本肺动脉高压治疗市场依给药途径分類的组成是怎样的？
  • 日本肺动脉高压治疗市场依最终用户分類的市场区隔如何？
  • 日本肺动脉高压治疗市场按地区分類的情况如何？
  • 请介绍日本肺动脉高压治疗市场价值链的各个环节。
  • 日本肺动脉高压治疗市场的主要驱动因素和挑战是什么？
  • 日本肺动脉高压治疗市场的结构是怎么样的？主要参与者有哪些？
  • 日本肺动脉高压治疗药物市场竞争程度如何？

目录

第一章：序言

第二章：调查范围与调查方法

  • 调查目标
  • 相关利益者
  • 数据来源
  • 市场估值
  • 调查方法

第三章执行摘要

第四章：日本肺动脉高压治疗市场－简介

  • 概述
  • 市场动态
  • 产业趋势
  • 竞争资讯

第五章 日本肺动脉高压治疗市场概述

  • 过去和当前的市场趋势（2020-2025）
  • 市场预测（2026-2034）

第六章：日本肺动脉高压治疗市场－依药物类别细分

  • 内皮素受体拮抗剂（ERA）
  • 血管扩张剂
  • 磷酸二酯酶-5 (PDE-5) 抑制剂
  • 可溶性鸟苷酸环化酶（SGC）刺激剂
  • 钙离子通道阻断剂（CCBs）
  • 前列腺环素和前列腺环素类似物
  • 其他的

第七章 日本肺动脉高压治疗市场－依给药途径细分

  • 吸入
  • 注射
  • 口服

第八章：日本肺动脉高压治疗市场－依最终用户细分

  • 医院
  • 诊所
  • 其他的

第九章：日本肺动脉高压治疗市场：依地区划分

  • 关东地区
  • 关西、近畿地区
  • 中部地区
  • 九州和冲绳地区
  • 东北部地区
  • 中国地区
  • 北海道地区
  • 四国地区

第十章：日本肺动脉高压治疗市场：竞争格局

  • 概述
  • 市场结构
  • 市场公司定位
  • 关键成功策略
  • 竞争对手仪錶板
  • 企业估值象限

第十一章主要企业概况

第十二章：日本肺动脉高压治疗市场：产业分析

  • 驱动因素、限制因素和机会
  • 波特五力分析
  • 价值链分析

第十三章附录

简介目录
Product Code: SR112026A34767

The Japan pulmonary arterial hypertension drugs market size reached USD 497.0 Million in 2025 . Looking forward, IMARC Group expects the market to reach USD 795.8 Million by 2034 , exhibiting a growth rate (CAGR) of 5.37% during 2026-2034 . The increased disease awareness, advancements in diagnostic technologies, introduction of novel therapies, a growing focus on personalized medicines, substantial research and development (R&D) investments, and regulatory support facilitating expedited drug approvals are among the key factors driving the market growth.

JAPAN PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET TRENDS:

Advancements in Targeted Therapies and Personalized Medicine

A key trend propelling the growth of Japan's pulmonary arterial hypertension (PAH) drugs market is the increasing focus on targeted therapies and personalized medicine. These advanced treatments are designed to address the root causes of pulmonary arterial hypertension by specifically targeting molecular pathways such as endothelin, nitric oxide, and prostacyclin, which are involved in disease progression. The rise of personalized treatments, fueled by advances in biomarker identification and genomic testing, allows for more customized therapies that are tailored to a patient's genetic profile, enhancing efficacy and minimizing side effects. This upward trend reflects the ongoing evolution in PAH treatment, aimed at improving patient outcomes through precision medicine.

To get more information on this market Request Sample

Increase in Disease Awareness and Early Diagnosis

Increasing awareness about PAH is significantly contributing to the growth of Japan's PAH drugs market. Historically underdiagnosed due to its non-specific symptoms, PAH is now being recognized more widely by both patients and healthcare providers. Public awareness campaigns led by health organizations, hospitals, and pharmaceutical companies are educating the public and medical professionals about the importance of early diagnosis and timely intervention. In parallel, advancements in diagnostic technologies, including echocardiography, right heart catheterization, and biomarkers, have enabled earlier detection of the disease, driving greater demand for PAH therapies. In addition to this, the number of diagnosed PAH patients in Japan is gradually increasing, underscoring the positive impact of heightened awareness and early detection. This growing recognition is fueling the demand for treatment, further catalyzing the market's expansion.

JAPAN PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET SEGMENTATION:

Drug Class Insights:

  • Endothelin Receptor Antagonists (ERAs)
  • Vasodilators
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Soluble Guanylate Cyclase (SGC) Stimulators
  • Calcium Channel Blockers (CCBs)
  • Prostacyclin and Prostacyclin Analogs
  • Others
  • Endothelin Receptor Antagonists (ERAs)
  • Vasodilators
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Soluble Guanylate Cyclase (SGC) Stimulators
  • Calcium Channel Blockers (CCBs)
  • Prostacyclin and Prostacyclin Analogs
  • Others

Route of Administration Insights:

  • Inhalation
  • Injectable
  • Oral Administration
  • Inhalation
  • Injectable
  • Oral Administration

End User Insights:

  • Access the comprehensive market breakdown Request Sample
  • Hospitals
  • Clinics
  • Others
  • Hospitals
  • Clinics
  • Others

Regional Insights:

  • Kanto Region
  • Kansai/Kinki Region
  • Central/Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
  • Kanto Region
  • Kansai/Kinki Region
  • Central/Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
  • The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

  • KEY QUESTIONS ANSWERED IN THIS REPORT
  • How has the Japan pulmonary arterial hypertension drugs market performed so far and how will it perform in the coming years?
  • What is the breakup of the Japan pulmonary arterial hypertension drugs market on the basis of drug class?
  • What is the breakup of the Japan pulmonary arterial hypertension drugs market on the basis of route of administration?
  • What is the breakup of the Japan pulmonary arterial hypertension drugs market on the basis of end user?
  • What is the breakup of the Japan pulmonary arterial hypertension drugs market on the basis of region?
  • What are the various stages in the value chain of the Japan pulmonary arterial hypertension drugs market?
  • What are the key driving factors and challenges in the Japan pulmonary arterial hypertension drugs?
  • What is the structure of the Japan pulmonary arterial hypertension drugs market and who are the key players?
  • What is the degree of competition in the Japan pulmonary arterial hypertension drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Pulmonary Arterial Hypertension Drugs Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Pulmonary Arterial Hypertension Drugs Market Landscape

  • 5.1 Historical and Current Market Trends (2020-2025)
  • 5.2 Market Forecast (2026-2034)

6 Japan Pulmonary Arterial Hypertension Drugs Market - Breakup by Drug Class

  • 6.1 Endothelin Receptor Antagonists (ERAs)
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2020-2025)
    • 6.1.3 Market Forecast (2026-2034)
  • 6.2 Vasodilators
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2020-2025)
    • 6.2.3 Market Forecast (2026-2034)
  • 6.3 Phosphodiesterase-5 (PDE-5) Inhibitors
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2020-2025)
    • 6.3.3 Market Forecast (2026-2034)
  • 6.4 Soluble Guanylate Cyclase (SGC) Stimulators
    • 6.4.1 Overview
    • 6.4.2 Historical and Current Market Trends (2020-2025)
    • 6.4.3 Market Forecast (2026-2034)
  • 6.5 Calcium Channel Blockers (CCBs)
    • 6.5.1 Overview
    • 6.5.2 Historical and Current Market Trends (2020-2025)
    • 6.5.3 Market Forecast (2026-2034)
  • 6.6 Prostacyclin and Prostacyclin Analogs
    • 6.6.1 Overview
    • 6.6.2 Historical and Current Market Trends (2020-2025)
    • 6.6.3 Market Forecast (2026-2034)
  • 6.7 Others
    • 6.7.1 Historical and Current Market Trends (2020-2025)
    • 6.7.2 Market Forecast (2026-2034)

7 Japan Pulmonary Arterial Hypertension Drugs Market - Breakup by Route of Administration

  • 7.1 Inhalation
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2020-2025)
    • 7.1.3 Market Forecast (2026-2034)
  • 7.2 Injectable
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2020-2025)
    • 7.2.3 Market Forecast (2026-2034)
  • 7.3 Oral Administration
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2020-2025)
    • 7.3.3 Market Forecast (2026-2034)

8 Japan Pulmonary Arterial Hypertension Drugs Market - Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2020-2025)
    • 8.1.3 Market Forecast (2026-2034)
  • 8.2 Clinics
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2020-2025)
    • 8.2.3 Market Forecast (2026-2034)
  • 8.3 Others
    • 8.3.1 Historical and Current Market Trends (2020-2025)
    • 8.3.2 Market Forecast (2026-2034)

9 Japan Pulmonary Arterial Hypertension Drugs Market - Breakup by Region

  • 9.1 Kanto Region
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2020-2025)
    • 9.1.3 Market Breakup by Drug Class
    • 9.1.4 Market Breakup by Route of Administration
    • 9.1.5 Market Breakup by End User
    • 9.1.6 Key Players
    • 9.1.7 Market Forecast (2026-2034)
  • 9.2 Kansai/Kinki Region
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2020-2025)
    • 9.2.3 Market Breakup by Drug Class
    • 9.2.4 Market Breakup by Route of Administration
    • 9.2.5 Market Breakup by End User
    • 9.2.6 Key Players
    • 9.2.7 Market Forecast (2026-2034)
  • 9.3 Central/ Chubu Region
    • 9.3.1 Overview
    • 9.3.2 Historical and Current Market Trends (2020-2025)
    • 9.3.3 Market Breakup by Drug Class
    • 9.3.4 Market Breakup by Route of Administration
    • 9.3.5 Market Breakup by End User
    • 9.3.6 Key Players
    • 9.3.7 Market Forecast (2026-2034)
  • 9.4 Kyushu-Okinawa Region
    • 9.4.1 Overview
    • 9.4.2 Historical and Current Market Trends (2020-2025)
    • 9.4.3 Market Breakup by Drug Class
    • 9.4.4 Market Breakup by Route of Administration
    • 9.4.5 Market Breakup by End User
    • 9.4.6 Key Players
    • 9.4.7 Market Forecast (2026-2034)
  • 9.5 Tohoku Region
    • 9.5.1 Overview
    • 9.5.2 Historical and Current Market Trends (2020-2025)
    • 9.5.3 Market Breakup by Drug Class
    • 9.5.4 Market Breakup by Route of Administration
    • 9.5.5 Market Breakup by End User
    • 9.5.6 Key Players
    • 9.5.7 Market Forecast (2026-2034)
  • 9.6 Chugoku Region
    • 9.6.1 Overview
    • 9.6.2 Historical and Current Market Trends (2020-2025)
    • 9.6.3 Market Breakup by Drug Class
    • 9.6.4 Market Breakup by Route of Administration
    • 9.6.5 Market Breakup by End User
    • 9.6.6 Key Players
    • 9.6.7 Market Forecast (2026-2034)
  • 9.7 Hokkaido Region
    • 9.7.1 Overview
    • 9.7.2 Historical and Current Market Trends (2020-2025)
    • 9.7.3 Market Breakup by Drug Class
    • 9.7.4 Market Breakup by Route of Administration
    • 9.7.5 Market Breakup by End User
    • 9.7.6 Key Players
    • 9.7.7 Market Forecast (2026-2034)
  • 9.8 Shikoku Region
    • 9.8.1 Overview
    • 9.8.2 Historical and Current Market Trends (2020-2025)
    • 9.8.3 Market Breakup by Drug Class
    • 9.8.4 Market Breakup by Route of Administration
    • 9.8.5 Market Breakup by End User
    • 9.8.6 Key Players
    • 9.8.7 Market Forecast (2026-2034)

10 Japan Pulmonary Arterial Hypertension Drugs Market - Competitive Landscape

  • 10.1 Overview
  • 10.2 Market Structure
  • 10.3 Market Player Positioning
  • 10.4 Top Winning Strategies
  • 10.5 Competitive Dashboard
  • 10.6 Company Evaluation Quadrant

11 Profiles of Key Players

  • 11.1 Company A
    • 11.1.1 Business Overview
    • 11.1.2 Products Offered
    • 11.1.3 Business Strategies
    • 11.1.4 SWOT Analysis
    • 11.1.5 Major News and Events
  • 11.2 Company B
    • 11.2.1 Business Overview
    • 11.2.2 Products Offered
    • 11.2.3 Business Strategies
    • 11.2.4 SWOT Analysis
    • 11.2.5 Major News and Events
  • 11.3 Company C
    • 11.3.1 Business Overview
    • 11.3.2 Products Offered
    • 11.3.3 Business Strategies
    • 11.3.4 SWOT Analysis
    • 11.3.5 Major News and Events
  • 11.4 Company D
    • 11.4.1 Business Overview
    • 11.4.2 Products Offered
    • 11.4.3 Business Strategies
    • 11.4.4 SWOT Analysis
    • 11.4.5 Major News and Events
  • 11.5 Company E
    • 11.5.1 Business Overview
    • 11.5.2 Products Offered
    • 11.5.3 Business Strategies
    • 11.5.4 SWOT Analysis
    • 11.5.5 Major News and Events

12 Japan Pulmonary Arterial Hypertension Drugs Market - Industry Analysis

  • 12.1 Drivers, Restraints, and Opportunities
    • 12.1.1 Overview
    • 12.1.2 Drivers
    • 12.1.3 Restraints
    • 12.1.4 Opportunities
  • 12.2 Porters Five Forces Analysis
    • 12.2.1 Overview
    • 12.2.2 Bargaining Power of Buyers
    • 12.2.3 Bargaining Power of Suppliers
    • 12.2.4 Degree of Competition
    • 12.2.5 Threat of New Entrants
    • 12.2.6 Threat of Substitutes
  • 12.3 Value Chain Analysis

13 Appendix